Market Research Logo

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK

Summary

GlobalData, the industry analysis specialist, has released its new report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK”. The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of the UK. The report identifies the key trends in the healthcare market and provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the UK. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData’s team of industry experts.

In 2014, the UK`s population was approximately 64.2 million. The major factors contributing to the growth in the population are increase in net migration and decrease in death rate. The UK policymakers are now presented with the problems of a Eurozone crisis, a declining population of the working age group and an increasing elderly population. The pharmaceutical market in the UK was estimated at $28.8 billion in 2015 and is expected to reach approximately $43.2 billion by 2020 with a projected Compound Annual Growth Rate (CAGR) of 8.4%. The medical devices market size was approximately $14.4 billion in 2015 and is expected to reach approximately $17.9 billion by 2020 with a projected CAGR of 4.5%.

The positive trends in the UK healthcare market can be attributed primarily to -

  • Increasing elderly population
  • Universal healthcare insurance
  • High degree of access to healthcare facilities
Scope

The report provides information on the healthcare, regulatory and reimbursement landscape of the UK. The scope includes -
  • Overview of the pharmaceutical and medical devices market of the UK including the market size, market segmentation, key drivers and barriers.
  • Profile and SWOT analysis of the major players in the pharmaceutical and medical devices market. The key players covered for the pharmaceutical market are Pfizer, GlaxoSmithKline, Novartis, Roche and Merck. The key players covered for the medical devices market are Essilor International, GlaxoSmithKline, DePuy Companies, Johnson & Johnson and B.Braun.
  • Insightful review on the reimbursement and regulatory landscape. Analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices.
  • A detailed analysis of the political and economic environment of the UK including the economic indicators, demographics, healthcare infrastructure and healthcare expenditure.
  • An overview of the opportunities and challenges for growth that exist in the healthcare market of the UK.
Reasons to buy

The report on the UK comprehensively covers both the pharmaceutical and the medical devices markets of the UK. The report will enhance your decision making capability. It will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the healthcare market of the UK.
  • Drive revenue by understanding the key trends, and reimbursement and regulatory policies, pharmaceutical and medical devices market segments and companies likely to impact the the UK healthcare market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of the various competitors.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the maximum opportunities for consolidations, investments and strategic partnerships.
  • Identify, understand and capitalize on the opportunities and challenges in the healthcare market of the UK.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 GlobalData Report Guidance
3 Overview of the Pharmaceutical and Medical Device Markets
3.1 Pharmaceutical Market
3.1.1 Market Overview
3.1.2 Pharmaceutical Exports and Imports
3.1.3 Supply Channels
3.1.4 Market Segments
3.1.5 Major Therapeutic Areas
3.1.6 Major Companies
3.2 Medical Device Market
3.2.1 Market Overview
3.2.2 Overview of Top Five Segments
3.2.3 Diagnostic market
3.2.4 Major Players
3.3 Market Drivers and Barriers
3.3.1 Drivers
3.3.2 Barriers
4 Market Access
4.1 Reimbursement and Payer Landscape
4.1.1 Overview of Healthcare System
4.1.2 Reimbursement Process
4.1.3 Overview of Insurance Providers
4.1.4 Patient Share in Healthcare Spending
4.1.5 Drug Price Change
4.1.6 Pricing Policies
4.2 Regulatory Landscape
4.2.1 Overview of Regulatory Agencies
4.2.2 Market Authorization Procedure for Pharmaceutical Products
4.2.3 New Medical Device Approval Process
4.2.4 Licensing Process for Pharmaceutical Manufacturing
4.2.5 Intellectual Property Rights
4.2.6 Clinical Trial Regulations
4.2.7 Pharmaceutical Advertising Regulations
4.2.8 Pharmacy Regulations
4.2.9 Labeling and Packaging Regulations
5 Country Analysis
5.1 Political Environment
5.1.1 Political Structure
5.1.2 Analysis of the Current Political Environment
5.1.3 Healthcare Policy Initiatives
5.2 Economic Landscape
5.3 Economic Indicators
5.3.1 Gross Domestic Product
5.3.2 Gross National Income
5.3.3 Inflation
5.3.4 Currency Exchange Rate
5.3.5 Foreign Direct Investment
5.3.6 Foreign Exchange Reserves
5.3.7 Trade Balance
5.3.8 Government Structural Balance
5.3.9 General Government Gross Debt
5.3.10 External Debt
5.3.11 Major Industries
5.4 Demographics
5.4.1 Population
5.4.2 Education and Literacy
5.4.3 Employment
5.4.4 Disease Burden
5.5 Healthcare Infrastructure
5.5.1 Healthcare Facilities
5.5.2 Healthcare Parameters
5.5.3 Environmental Health
5.5.4 Healthcare Personnel
5.6 Healthcare Expenditure
5.6.1 Overview
5.6.2 Components of Healthcare Spending
5.6.3 Public and Private Sector Share
5.6.4 Spending in Pharmaceutical R&D
5.7 Trade Associations
5.7.1 Association of the British Pharmaceutical Industry (ABPI)
5.7.2 British In Vitro Diagnostics Association (BIVDA)
5.7.3 National Pharmacy Association (NPA)
5.7.4 Association of British Healthcare Industries (ABHI)
5.7.5 British Generic Manufacturers Association (BGMA)
5.8 Trade Fairs
6 Opportunities and Challenges
6.1 Opportunities
6.2 Challenges
7 Appendix
7.1 Abbreviations
7.2 Bibliography
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasts
7.3.4 Expert Panel
7.4 Disclaimer
1.1 List of Tables
Table 1: Pharmaceutical Market, UK, Revenue ($bn), 2008-2015
Table 2: Pharmaceutical Market, UK, Revenue ($bn), 2016-2020
Table 3: Pharmaceutical Market, UK, Revenue by Exports and Imports ($bn), 2008-2015
Table 4: Major Therapeutic Areas, UK, Prescribing cost ($bn) , 2015
Table 5: Pharmaceutical Market, UK, NHS Gross Expenditure on Neurological Issues ($bn), 2008-2015
Table 6: Pharmaceutical Market, UK, NHS Gross Expenditure on Endocrine System Issues ($bn), 2008-2015
Table 7: Pharmaceutical Market, UK, NHS Gross Expenditure on Respiratory System Problems ($bn), 2008-2015
Table 8: Pharmaceutical Market, UK, NHS Gross Expenditure on Cardiovascular System Problems ($bn), 2008-2015
Table 9: Pharmaceutical Market, UK, NHS Gross Expenditure on Nutrition and Blood Problems ($bn), 2008-2015
Table 10: Pharmaceutical Market, Pfizer, Global, Major Products by Revenue ($bn) and Annual Growth (%), Revenue, 2014
Table 11: Pharmaceutical Market, Pfizer, Global, Late-Stage Pipeline, 2015
Table 12: Pharmaceutical Market, GlaxoSmithKline, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2014
Table 13: Pharmaceutical Market, GlaxoSmithKline, Global, Late-Stage Pipeline, 2015
Table 14: Pharmaceutical Market, Novartis, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013
Table 15: Pharmaceutical Market, Novartis, Global, Planned Filings, 2016-2019
Table 16: Pharmaceutical Market, Roche, Global, Major Products, Revenue ($m) and Annual Growth (%), 2013
Table 17: Pharmaceutical Market, Roche, Global, Late-stage Pipeline, 2013
Table 18: Pharmaceutical Market, Merck, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013
Table 19: Pharmaceutical Market, Merck, Global, Late-Stage Pipeline, 2014
Table 20: Medical Device Market, UK, Revenue ($bn), 2008-2015
Table 21: Medical Device Market, UK, Revenue ($bn), 2016-2020
Table 22: Medical Device Market, UK, Revenue ($bn), 2014
Table 23: Medical Device Market, UK, Orthopedic Devices Market, Revenue ($bn), 2008-2015
Table 24: Medical Device Market, UK, Orthopedic Devices Market, Market Share (%), 2014
Table 25: Medical Device Market, UK, Ophthalmic Devices, Market Revenue ($bn), 2008-2015
Table 26: Medical Device Market, UK, Ophthalmic Devices, Market Share (%), 2014
Table 27: Medical Device Market, UK, Wound Care Management Market, Revenue ($bn), 2008-2015
Table 28: Medical Device Market, UK, Wound Care Management, Market Share (%), 2012
Table 29: Medical Device Market, UK, Cardiovascular Device Market, Revenue ($bn), 2008-2015
Table 30: Medical Device Market, UK, Cardiovascular Device Market, Market Share, 2012
Table 31: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Revenue ($bn), 2008-2015
Table 32: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Share (%), 2012
Table 33: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2008-2015
Table 34: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2016-2020
Table 35: Medical Device Market, GlaxoSmithKline, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2014
Table 36: Healthcare Spending, UK, Out-of-pocket Expenditure (% of Private Expenditure on Health), 2008-2015
Table 37: Market Access, UK, Drug Price Change (%), 2008-2015
Table 38: Market Access, UK, Schedule of Patent Fees, 2015
Table 39: Market Access, UK, Schedule of Trademark Fees, 2015
Table 40: Market Access, UK, Clinical Trials Application Fees, 2015
Table 41: Market Access, UK, Clinical trials application fees, 2015
Table 42: Economic Indicators, UK, GDP per Capita ($), 2008-2015
Table 43: Economic Indicators, UK, GDP per Capita ($), 2016-2020
Table 44: Economic Indicators, UK, GDP Annual Growth (%), 2008-2015
Table 45: Economic Indicators, UK, GDP Annual Growth (%), 2016-2020
Table 46: Economic Indicators, UK, National Income ($ tn), 2008-2014
Table 47: Economic Indicators, UK, Average Consumer Price Index, 2008-2015
Table 48: Economic Indicators, UK Average Consumer Price Index, 2016-2020
Table 49: Economic Indicators, UK, Average Consumer Price Annual Change (%), 2008-2014
Table 50: Economic Indicators, UK, Currency Exchange Rate (£ to $), 2008-2014
Table 51: Economic Indicators, UK, FDI ($bn), 2008-2014
Table 52: Economic Indicators, UK, Foreign Exchange Reserves ($bn), 2008-2014
Table 53: Economic Indicators, UK, Imports of Goods and Services ($bn), 2008-2014
Table 54: Economic Indicators, UK, Exports of Goods and Services ($bn), 2008-2014
Table 55: Economic Indicators, UK, Government Structural Balance ($bn), 2008-2014
Table 56: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2008-2015
Table 57: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2016-2020
Table 58: Economic Indicators, UK, External Debt ($tr), 2008-2014
Table 59: Economic Indicators, UK, Major Industries, National Income by Industry ($bn), 2013
Table 60: Demographics, UK, Population (million), 2008-2014
Table 61: Demographics, UK, Population Forecast (million), 2016-2020
Table 62: Demographics, UK, Urban and Rural Population (%), 2008-2014
Table 63: Demographics, UK, Population Distribution by Age Group (%), 2008-2015
Table 64: Demographics, UK, Population Distribution by Age Group (%), 2016-2020
Table 65: Demographics, UK, Births (per 1,000 Population), 2008-2014
Table 66: Demographics, UK, Mortality (per 1,000 Population), 2008-2014
Table 67: Demographics, UK, Major Causes of Mortality (%), 2014
Table 68: Demographics, UK, Infant Mortality (per 1,000 Live Births), 2008-2014
Table 69: Demographics, UK, Immunization Rate (%), 2013
Table 70: Demographics, UK, Major Causes of Male Mortality (‘000), 2014
Table 71: Demographics, UK, Major Causes of Female Mortality (‘000), 2014
Table 72: Demographics, UK, Gender Ratio (M/F), 2008-2014
Table 73: Demographics, UK, Life Expectancy at Birth (Years), 2008-2014
Table 74: Demographics, UK, Gross Enrollment (%), 2008-2015
Table 75: Demographics, UK, Unemployment Rate (%), 2008-2014
Table 76: Demographics, UK, Disease Burden, DALYs (per 100,000 population), 2013
Table 77: Healthcare Infrastructure, UK, Beds by Type of Service, 2008-2014
Table 78: Healthcare Infrastructure, UK, Diagnostic Equipment (Per Million Population), 2008-2014
Table 79: Healthcare Infrastructure, UK, Hospital Beds (per 1,000 Population), 2008-2014
Table 80: Healthcare Infrastructure, UK, Doctors (per 1,000 population), 2008-2014
Table 81: Healthcare Infrastructure, UK, CO2 emissions (million), 2008-2014
Table 82: Healthcare Infrastructure, UK, CH4 emissions (million tons), 2008-2014
Table 83: Healthcare Infrastructure, UK, PM10 (µg/m3), 2008-2014
Table 84: Healthcare Infrastructure, UK, Nurses (Per 1,000 Population), 2008-2014
Table 85: Healthcare Infrastructure, UK, Pharmacists (per 1,000 Population), 2008-2014
Table 86: Healthcare Infrastructure, UK, Dentists (Per 1,000 Population), 2008-2014
Table 87: Healthcare Expenditure, UK, Healthcare Expenditure (% of GDP), 2008-2014
Table 88: Healthcare Expenditure , UK, Consumption Expenditure on Medical Goods and Services, Share (%), 2013
Table 89: Healthcare Expenditure, UK, Public and Private Share of Healthcare Expenditure (%), 2008-2014
Table 90: Healthcare Expenditure, UK, Pharmaceutical R&D Expenditure ($bn), 2008-2014
Table 91: Major Healthcare Trade Fairs, UK, 2016
1.2 List of Figures
Figure 1: Pharmaceutical Market, UK, Revenue ($bn), 2008-2015
Figure 2: Pharmaceutical Market, UK, Revenue ($bn), 2016-2020
Figure 3: Pharmaceutical Market, UK, Revenue by Exports and Imports ($bn), 2008-2015
Figure 4: Pharmaceutical Market, UK, Supply Channels, 2014
Figure 5: Pharmaceutical Market, UK, Generic Launch, 2013
Figure 6: Major Therapeutic Areas, UK, Prescribing Cost ($bn), 2015
Figure 7: Pharmaceutical Market, UK, NHS Gross Expenditure on Neurological Issues ($bn), 2008-2015
Figure 8: Pharmaceutical Market, UK, NHS Gross Expenditure on Endocrine System Issues ($bn), 2008-2015
Figure 9: Pharmaceutical Market, UK, NHS Gross Expenditure on Respiratory System Issues ($bn), 2008-2015
Figure 10: Pharmaceutical Market, UK, NHS Gross Expenditure on Cardiovascular System Issues ($bn), 2008-2015
Figure 11: Pharmaceutical Market, UK, NHS Gross Expenditure on Nutrition and Blood Issues ($bn), 2008-2015
Figure 12: Medical Device Market, UK, Revenue ($bn), 2008-2015
Figure 13: Medical Device Market, UK, Revenue ($bn), 2016-2020
Figure 14: Medical Device Market, UK, Revenue ($bn), 2014
Figure 15: Medical Device Market, UK, Orthopedic Devices Market, Revenue ($bn), 2008-2015
Figure 16: Medical Device Market, UK, Orthopedic Devices Market, Market Share (%), 2014
Figure 17: Medical Device Market, UK, Ophthalmic Devices, Market Revenue ($bn), 2008-2015
Figure 18: Medical Device Market, UK, Ophthalmic Devices Market Share (%), 2012
Figure 19: Medical Device Market, UK, Wound Care Management Market, Revenue ($bn), 2008-2015
Figure 20: Medical Device Market, UK, Wound Care Management, Market Share (%), 2012
Figure 21: Medical Device Market, UK, Cardiovascular Device Market, Revenue ($bn), 2008-2015
Figure 22: Medical Device Market, UK, Cardiovascular Device Market, Share (%), 2012
Figure 23: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Revenue ($bn), 2008-2015
Figure 24: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Share (%), 2012
Figure 25: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2008-2015
Figure 26: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2016-2020
Figure 27: Healthcare Market, UK, Drivers and Barriers, 2015
Figure 28: Healthcare System, UK, 2015
Figure 29: Healthcare Spending, UK, Out-of-pocket Expenditure (% of Private Expenditure on Health), 2008-2015
Figure 30: Market Access, UK, Drug Price Change (%), 2008-2015
Figure 31 Healthcare System, UK, MHRA Structure, 2015
Figure 32: Healthcare System, UK, National Procedure for Market Authorization, 2015
Figure 33: Healthcare System, EU, Centralized Procedure, Pre-Submission, 2015
Figure 34: Healthcare System, EU, Centralized Procedure, Marketing Authorization, Pre-Opinion Phase, 2015
Figure 35: Healthcare System, EU, Centralized Procedure, Marketing Authorization, Post-opinion Phase, 2015
Figure 36: Healthcare System, EU, Decentralized Procedure, 2015
Figure 37: Healthcare System, EU, Mutual Recognition Procedure, 2015
Figure 38: Healthcare System, EU, Conformity Assessment of Class I Medical Devices, 2013
Figure 39: Healthcare System, EU, Conformity Assessment of Class IIa Medical Devices, 2013
Figure 40: Healthcare System, EU, Conformity Assessment of Class IIb Medical Devices, 2013
Figure 41: Healthcare System, EU, Conformity Assessment of Class III Medical Devices, 2013
Figure 42: Healthcare System, UK, Patent Approval Process, 2015
Figure 43: Healthcare System, UK, Clinical Trial Regulation Process for Medicines, 2015
Figure 44: Healthcare System, UK, Clinical Trial Regulation Process for Medical Devices, 2013
Figure 45: Economic Indicators, UK, GDP per Capita ($), 2008-2015
Figure 46: Economic Indicators, UK, GDP per Capita ($), 2016-2020
Figure 47: Economic Indicators, UK, GDP Annual Growth (%), 2008-2015
Figure 48: Economic Indicators, UK, GDP Annual Growth (%), 2016-2020
Figure 49: Economic Indicators, UK, National Income ($tn), 2008-2014
Figure 50: Economic Indicators, UK, Average Consumer Price Index, 2008-2015
Figure 51: Economic Indicators, UK, Average Consumer Price Index, 2016-2020
Figure 52: Economic Indicators, UK, Average Consumer Price Annual Change (%), 2008-2014
Figure 53: Economic Indicators, UK, Currency Exchange Rate ($ to £), 2008-2014
Figure 54: Economic Indicators, UK, FDI ($bn), 2008-2014
Figure 55: Economic Indicators, UK, Foreign Exchange Reserves ($bn), 2008-2014
Figure 56: Economic Indicators, UK, Imports of Goods and Services ($bn), 2008-2014
Figure 57: Economic Indicators, UK, Exports of Goods and Services ($bn), 2008-2014
Figure 58: Economic Indicators, UK, Government Structural Balance ($bn), 2008-2014
Figure 59: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2008-2015
Figure 60: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2016-2020
Figure 61: Economic Indicators, UK, External Debt ($tn), 2008-2014
Figure 62: Economic Indicators, UK, Major Industries, Gross Value Added ($bn), 2013
Figure 63: Demographics, UK, Population (million), 2008-2015
Figure 64: Demographics, UK, Population (million), 2016-2020
Figure 65: Demographics, UK, Urban and Rural Population (%), 2008-2014
Figure 66: Demographics, UK, Population Distribution by Age Group (%), 2008-2015
Figure 67: Demographics, UK, Population Distribution by Age Group (%), 2016-2020
Figure 68: Demographics, UK, Births (per 1,000 Population), 2008-2014
Figure 69: Demographics, UK, Mortality (per 1,000 Population), 2008-2014
Figure 70: Demographics, UK, Major Causes of Mortality (%), 2014
Figure 71: Demographics, UK, Infant Mortality (per 1,000 Live Births), 2008-2014
Figure 72: Demographics, UK, Immunization Rate (%), 2013
Figure 73: Demographics, UK, Major Causes of Male Mortality (‘000), 2014
Figure 74: Demographics, UK, Major Causes of Female Mortality (‘000), 2014
Figure 75: Demographics, UK, Gender Ratio (M/F), 2008-2014
Figure 76: Demographics, UK, Life Expectancy at Birth (Years), 2008-2014
Figure 77: Demographics, UK, Gross Enrollment (%), 2008-2015
Figure 78: Demographics, UK, Unemployment Rate (%), 2008-2014
Figure 79: Demographics, UK Disease Burden, DALYs (per 100,000 population), 2013
Figure 80: Healthcare Infrastructure, UK, Beds by Type of Service, 2008-2014
Figure 81: Healthcare Infrastructure, UK, Diagnostic Equipment (Per Million Population), 2008-2014
Figure 82: Healthcare Infrastructure, UK, Hospital Beds (Per 1,000 Population), 2008-2014
Figure 83: Healthcare Infrastructure, UK, Doctors (per 1,000 population), 2008-2014
Figure 84: Healthcare Infrastructure, UK, CO2 emissions (million tons), 2008-2014
Figure 85: Healthcare Infrastructure, UK, CH4 emissions (million tons)2008-2014
Figure 86: Healthcare Infrastructure, UK, PM10 (µg/m3), 2008-2014
Figure 87: Healthcare Infrastructure, UK, Nurses (Per 1,000 Population), 2008-2014
Figure 88: Healthcare Infrastructure, UK, Pharmacists (per 1,000 Population), 2008-2014
Figure 89: Healthcare Infrastructure, UK, Dentists (Per 1,000 Population), 2008-2014
Figure 90: Healthcare Expenditure, UK, Healthcare Expenditure (% of GDP), 2008-2014
Figure 91: Healthcare Expenditure , UK, Consumption Expenditure on Medical Goods and Services, Share (%), 2013
Figure 92: Healthcare Expenditure, UK, Public and Private Share of Healthcare Expenditure (%), 2008-2014
Figure 93: Healthcare Expenditure, UK, Pharmaceutical R&D Expenditure ($bn), 2008-2014
Figure 94: Healthcare Market, UK, Opportunities and Challenges, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report